Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595385 | 1.00 | PARP1 (0.56) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL29082758 | 0.91 | PARP1 (0.53) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL76627 | 0.87 | PARP1 (0.74) | PARP1PRAP1TNKSTNKS2 | |
| SCHEMBL78100 | 0.85 | PARP1 (0.65) | PARP1PRAP1TNKSTNKS2 | |
| SCHEMBL87269 | 0.85 | PARP1 (0.59) | PARP1TNKSTNKS2 | |
| SCHEMBL4183468 | 0.83 | PARP1 (0.79) | PARP1PRAP1TNKSTNKS2 | |
| SCHEMBL87122 | 0.82 | CYP3A4 (0.52) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL29466162 | 0.82 | PARP1 (0.70) | PARP1TNKSTNKS2 | |
| SCHEMBL29403857 | 0.82 | PARP1 (0.70) | PARP1TNKSTNKS2 | |
| SCHEMBL78452 | 0.82 | PARP1 (0.70) | PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP1 1973/4885CYP3A4 184/4885CYP2C9 248/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP1 1973/4885CYP3A4 184/4885CYP2C9 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.